ADPT - Adaptive Biotechnologies Corp
IEX Last Trade
6.42
-0.055 -0.857%
Share volume: 18,241
Last Updated: Thu 26 Dec 2024 08:30:20 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$6.48
-0.06
-0.85%
Fundamental analysis
17%
Profitability
0%
Dept financing
16%
Liquidity
75%
Performance
20%
Performance
5 Days
1.11%
1 Month
12.50%
3 Months
30.41%
6 Months
87.39%
1 Year
26.53%
2 Year
-10.63%
Key data
Stock price
$6.42
DAY RANGE
$6.33 - $6.50
52 WEEK RANGE
$2.46 - $7.07
52 WEEK CHANGE
$19.89
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Chad Robins
Region: US
Website: adaptivebiotech.com
Employees: 790
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: adaptivebiotech.com
Employees: 790
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It serves the life sciences research, clinical diagnostics, and drug discovery applications.
Recent news